1139. Novel Formulation SUBA-Itraconazole Prophylaxis in Patients With Hematological Malignancy or Undergoing Allogeneic Stem Cell Transplantation: Follow-up Survival Data

BACKGROUND: Despite the advantageous spectrum of activity of itraconazole, it is rarely used as a prophylactic agent due to limited bioavailability and intolerance of the conventional formulation. After the development of a novel formulation SUBA-itraconazole® (SUper BioAvailability), we undertook a...

Descripción completa

Detalles Bibliográficos
Autores principales: Lindsay, Julian, Sandaradura, Indy, Wong, Kelly, Arthur, Chris, Stevenson, William, Kerridge, Ian, Fay, Keith, Coyle, Luke, Greenwood, Matthew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255503/
http://dx.doi.org/10.1093/ofid/ofy210.972

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255503/
http://dx.doi.org/10.1093/ofid/ofy210.972

Ejemplares similares